Amy McKerrow, MD
Urology · Kalispell, MTNPI 1376598433
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Coloplast at 44.1% of the total. Reporting peaked in 2023 at $3,907 and has fallen 90.1% since, to $389 in 2025. Among urology clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $95.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$4K
- Medtronic$1K
- Valencia Technologies Corporation$1K
- Astellas Pharma US Inc$553
- Intuitive Surgical$534
- Axonics, Inc.$341
- plus $1K from 14 others
What the payments were for
- Travel & lodging$5,47158%
- Food & beverage$3,35336%
- Education$5776%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 17 | $4,142 |
| Medtronic(2 entities) | 12 | $1,245 |
| Valencia Technologies Corporation | 7 | $1,237 |
| Astellas Pharma US Inc | 11 | $553 |
| Intuitive Surgical | 2 | $534 |
| Axonics, Inc. | 5 | $341 |
| Procept Biorobotics Corporation | 4 | $314 |
| AbbVie(2 entities) | 9 | $286 |
| Johnson & Johnson | 8 | $267 |
| Boston Scientific | 5 | $119 |
| Amgen | 4 | $96 |
| Dendreon Pharmaceuticals LLC | 3 | $66 |
| AstraZeneca | 1 | $53 |
| Bayer | 3 | $44 |
| Calyxo, Inc. | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Innovation Technologies Inc | 1 | $14 |
| Pfizer | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$3,717
- INTERSTIM$972
- eCoin Device Kit$950
- Da Vinci Surgical System$534
- Axonics$236
- AQUABEAM SYSTEM$229
- RESTORELLE$201
How this compares
$9,401 in reported general payments places this provider in the 90th percentile of 45 urology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 282 | $166,085 |
| GemtesaVibegron | 43 | $23,268 |
| Estradiol | 67 | $6,371 |
| Potassium Citrate ErPotassium Citrate | 29 | $2,627 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 21 | $1,908 |
| Cephalexin | 116 | $1,396 |
| NitrofurantoinNitrofurantoin Macrocrystal | 23 | $1,376 |
| Trospium Chloride | 25 | $1,089 |
| Solifenacin Succinate | 46 | $945 |
| Tamsulosin Hcl | 87 | $731 |
| Finasteride | 56 | $729 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $537 |
| Cefdinir | 16 | $531 |
| Oxybutynin Chloride | 92 | $428 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $553 | $166,085282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 45 urology providers in Montana.
Other urology in Kalispell
- Sarabeth MartinKalispell$4K
- John AndenoroKalispell$3K
- Geraldine SheuKalispell$2K
- Jonathan MercerKalispell$2K
- Vassilis SiomosKalispell$2K
- Gregory AdamsKalispell$669
- Michael BersonKalispell$95
- Craig HinmanKalispell$29
- Christopher FukudaGreat Falls$19K
- Garrick SimmonsMissoula$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.